Literature DB >> 18781541

Urological implications of cyclophosphamide and ifosfamide.

Malcolm Lawson1, Arthur Vasilaras, Annamarie De Vries, Peter Mactaggart, David Nicol.   

Abstract

Cyclophosphamide and ifosfamide are commonly used cytotoxic medications that are indicated in a wide range of conditions, both benign and malignant. Complications of their use include well-recognized acute and chronic urological side-effects. Haemorrhagic cystitis, nephrotoxicity and transitional cell carcinoma can be directly attributed to the use of these agents, and are potentially fatal. Preventive measures can be used in an attempt to minimize the rate of complications. Urological intervention may be required in the acute and long-term management of patients who have received oxazaphosphorine agents. This article reviews current literature, sourced using a MEDLINE search of the keywords with cross-referencing. All articles were reviewed by abstract. Selection of articles was on the basis of randomized controlled trials and articles adding new or significant information.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781541     DOI: 10.1080/00365590701570953

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  12 in total

1.  Evaluation of the anti-inflammatory and urotoxicity ameliorative effects of γ-humulene containing active fraction of Emilia sonchifolia (L.) DC.

Authors:  Gilcy George Kallivalappil; Girija Kuttan
Journal:  Inflammopharmacology       Date:  2017-12-09       Impact factor: 4.473

2.  Effects of the hydroalcoholic extract of Phyllanthus niruri and its isolated compounds on cyclophosphamide-induced hemorrhagic cystitis in mouse.

Authors:  Vinícios T Boeira; Carlos E Leite; André A Santos; Maria I Edelweiss; João B Calixto; Maria M Campos; Fernanda B Morrone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-23       Impact factor: 3.000

Review 3.  The glycine deportation system and its pharmacological consequences.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Pharmacol Ther       Date:  2012-05-11       Impact factor: 12.310

4.  The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.

Authors:  S Bogiatzi; O Pagonopoulou; M Simopoulou; D Kareli; A Kouskoukis; Z Koutka; P Ipsilantis; T Lialiaris
Journal:  Cytotechnology       Date:  2013-08-15       Impact factor: 2.058

5.  Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective.

Authors:  Jemianne Bautista Jia; Chandana Lall; Temel Tirkes; Rajesh Gulati; Ramit Lamba; Scott C Goodwin
Journal:  Insights Imaging       Date:  2015-07-11

6.  Gamma-Glutamylcysteine Ethyl Ester Protects against Cyclophosphamide-Induced Liver Injury and Hematologic Alterations via Upregulation of PPARγ and Attenuation of Oxidative Stress, Inflammation, and Apoptosis.

Authors:  Sultan Alqahtani; Ayman M Mahmoud
Journal:  Oxid Med Cell Longev       Date:  2016-12-15       Impact factor: 6.543

7.  A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines.

Authors:  S G Shapiro; D W Knapp; Matthew Breen
Journal:  Canine Genet Epidemiol       Date:  2015-09-17

8.  Cyclophosphamide-induced Hepatotoxicity in Wistar Rats: The Modulatory Role of Gallic Acid as a Hepatoprotective and Chemopreventive Phytochemical.

Authors:  Ademola Adetokunbo Oyagbemi; Olutayo Temidayo Omobowale; Ebunoluwa Rachael Asenuga; Akinrinde Stephen Akinleye; Rachael Omolola Ogunsanwo; Adebowale Bernard Saba
Journal:  Int J Prev Med       Date:  2016-03-01

9.  Systemic treatment in breast cancer: a primer for radiologists.

Authors:  Aya Y Michaels; Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-11-13

10.  Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis.

Authors:  Evaristus C Mbanefo; Loc Le; Luke F Pennington; Justin I Odegaard; Theodore S Jardetzky; Abdulaziz Alouffi; Franco H Falcone; Michael H Hsieh
Journal:  FASEB J       Date:  2018-04-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.